Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 70 results for psoriasis

  1. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA199

  2. Bimekizumab for treating active psoriatic arthritis (TA916)

    Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    4 October 2023
    View recommendations

    Sections for TA916

  3. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA340

  4. Secukinumab biosimilar for treating plaque psoriasis TSID 11992

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further refined and validated to: - assess disease severity and impact in both non-specialist and specialist healthcare settings, to facilitate assessment, appropriate referral, treatment planning and measurement of outcomes - measure burden and cumulative effect of disease activity, severity and impact for people with both psoriasis and psoriatic arthritis?

    disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further...

    Research recommendation
    Published
    9 June 2015

  6. Rapid escalation to systemic treatments:- In people with psoriasis, does early intervention with systemic treatments improve the long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are there any clinical (for example demographic or phenotypic) or laboratory (for example genetic or immune) biomarkers that can be used to identify those most likely to benefit from this treatment approach?

    treatments:- In people with psoriasis, does early intervention with systemic treatments improve the long-term prognosis of...

    Research recommendation
    Published
    9 June 2015

  7. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA407

  8. Grenz rays therapy for inflammatory skin conditions (IPG236)

    Evidence-based recommendations on Grenz rays therapy for inflammatory skin conditions. This involves exposing the skin to low-energy, non-penetrative electromagnetic radiation.

    Interventional procedures guidance
    Published
    28 November 2007
    View recommendations

    Sections for IPG236

  9. Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

    generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility...

    Research recommendation
    Published
    15 October 2018

  10. Self-management:- Do structured psoriasis-focused self-management programmes improve patient confidence, wellbeing and disease control compared with standard care?

    Recommendation ID CG153/4 Question Self-management:- Do structured psoriasis-focused self-management programmes improve patient...

    Research recommendation
    Published
    9 June 2015

  11. Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other approaches to care (for example other systemic non-biological or biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk?

    biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or...

    Research recommendation
    Published
    9 June 2015

  12. Intravenous infusion of mesenchymal stromal cells in patients with severe recalcitrant psoriasis

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  13. Intravenous infusion of mesenchymal stromal cells in patients with severe recalcitrant psoriasis

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  14. Topical therapy:- In people of all ages with psoriasis: 1. How should topical therapies be used to maintain disease control i) safely; ii) effectively and iii) what are the health economic implications? 2. What are the risks of 'real life' long term corticosteroid use, are there particular people at risk and what strategies can be used to modify or avoid risks?

    CG153/5 Question Topical therapy:- In people of all ages with psoriasis: 1. How should topical therapies be used to maintain disease...

    Research recommendation
    Published
    9 June 2015

  15. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA177